rmdopen.bmj5d
Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives
The therapeutic window of opportunity in rheumatoid arthritis (RA) is often referred to. However, some have questioned whether such a period, in which the disease is more susceptible to ...
rmdopen.bmj9d
Novel insight into the aetiology of rheumatoid arthritis gained by a cross-tissue transcriptome-wide association study
Background Although genome-wide association studies (GWASs) have identified more than 100 loci associated with rheumatoid arthritis (RA) susceptibility, the causal genes and biological mechanisms ...
rmdopen.bmj11d
Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins
Objective Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We ...
rmdopen.bmj13d
Mixed connective tissue disease: state of the art on clinical practice guidelines
Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic ...
rmdopen.bmj14d
Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease characterised by the association of arthritis and psoriasis combined with other related conditions and comorbidities.
rmdopen.bmj20d
EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology
Objective Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these ...
rmdopen.bmj22d
A prediction model for progressive disease in systemic sclerosis
Objective To develop a model that assesses the risk for progressive disease in patients with systemic sclerosis (SSc) over the short term, in order to guide clinical management. Methods Baseline ...
rmdopen.bmj27d
Pollutants: a candidate as a new risk factor for osteoarthritis—results from a systematic literature review
Background Considering non-classical environmental risk factors for osteoarthritis (OA), a systematic literature review (SLR) was performed to summarise existing knowledge on associations between OA ...
rmdopen.bmj29d
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
Objective To report the efficacy, patient-reported, radiographic and safety outcomes of 4 years’ certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA). Methods RAPID-PsA ...
rmdopen.bmj1mon
Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers
Objectives The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general ...
rmdopen.bmj1mon
Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
Objectives Most studies on difficult-to-treat rheumatoid arthritis (D2T RA) have focused on established RA. Here, we analyse whether disease activity in the early stages of RA could influence ...